Literature DB >> 14698167

Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder.

Arturo Perez-Medrano1, Steven A Buckner, Michael J Coghlan, Robert J Gregg, Murali Gopalakrishnan, Michael E Kort, John K Lynch, Victoria E Scott, James P Sullivan, Kristi L Whiteaker, William A Carroll.   

Abstract

Thiourea derivatives were identified as glyburide-reversible potassium channel openers through high-throughput screening. Based on these findings, a number of novel cyanoguanidines were designed and synthesized, which hyperpolarized human bladder K(ATP) channels. These agents are potent full agonists in relaxing electrically-stimulated pig bladder strips. The synthesis, SAR and biological properties of these agents are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14698167     DOI: 10.1016/j.bmcl.2003.10.063

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Synthesis and analgesic activity evaluation of some agmatine derivatives.

Authors:  Hongxia He; Mengjia Liu; Zhibing Zheng; Ying Liu; Junhai Xiao; Ruibin Su; Chun Hu; Jin Li; Song Li
Journal:  Molecules       Date:  2006-06-12       Impact factor: 4.411

2.  Characterization of a novel ATP-sensitive K+ channel opener, A-251179, on urinary bladder relaxation and cystometric parameters.

Authors:  C-C Shieh; M E Brune; S A Buckner; K L Whiteaker; E J Molinari; I A Milicic; A C Fabiyi; A Daza; J D Brioni; W A Carroll; K Matsushita; M Yamada; Y Kurachi; M Gopalakrishnan
Journal:  Br J Pharmacol       Date:  2007-04-16       Impact factor: 8.739

3.  Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug.

Authors:  Henrik Lövborg; Robert Burman; Joachim Gullbo
Journal:  BMC Res Notes       Date:  2009-06-29

4.  Selective P2X(7) receptor antagonists for chronic inflammation and pain.

Authors:  William A Carroll; Diana Donnelly-Roberts; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2008-06-21       Impact factor: 3.765

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.